Observational studyJournal of neurology2018
Generalization after ocular onset in myasthenia gravis: a case series in Germany.
Observational study in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Association Between Immunotherapy and Generalization in Ocular Myasthenia Gravis as a Function of Antibody Status.Revista de neurologia · 2026Article
- Robotic thymectomy in myasthenia gravis: current evidence, outcomes, and future perspective.Journal of cardiothoracic surgery · 2026Review
- Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study.Journal of ophthalmology · 2026Article
- Is Isolated Inferior Rectus Weakness a Strong Indicator for Myasthenia Gravis?The British and Irish orthoptic journal · 2026Article
- Common features of rare disease patients in the emergency department: a systematised literature review.Orphanet journal of rare diseases · 2025Review
- Thymectomy in Ocular Myasthenia Gravis: Results Before and After Generalization and Prognostic Predictors of Outcomes.Journal of clinical medicine · 2025Article
- Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.Orphanet journal of rare diseases · 2025Observational
- Ocular Myasthenia gravis: determining the predictive factors of secondary generalisation.Acta neurologica Belgica · 2025Article
- Clinical Characteristics and Outcomes of Generalized Myasthenia Gravis in Malaysia: A Single-Center Experience.Journal of clinical neurology (Seoul, Korea) · 2024Article
- Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in Myasthenia Gravis.Frontiers in neurology · 2024Article
- Prognostic predictors of remission in ocular myasthenia gravis.Acta neurologica Belgica · 2023Article
- Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Observational
- The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review.The British and Irish orthoptic journal · 2023Article
- Ocular Myasthenia Gravis: A Current Overview.Eye and brain · 2023Review
- Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study.Frontiers in neurology · 2023Article
- Generalization of ocular myasthenia gravis 10 years after onset.Journal of neurology · 2022Observational
- Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset.Frontiers in neurology · 2022Article
- Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies.Neuro-ophthalmology (Aeolus Press) · 2022Article
- Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.Acta neurologica Belgica · 2021Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeApproximately, 50% of myasthenia gravis (MG) patients initially present with purely ocular symptoms. Of these, about 60% will develop secondary generalized MG, typically within 2 years. Risk factors for secondary generalization are still controversial. In this study, we reviewed clinical parameters, thymic pathologies and medical treatments of MG patients with purely ocular symptoms at onset to investigate risk factors for secondary generalization.
methodsIn this monocentric retrospective study, we reviewed consecutive patients who underwent robotic thymectomy between January 2003 and October 2017 in Charite Universitaetsmedizin Berlin. We used univariate and multivariate Cox proportional hazards regression models to identify factors associated with secondary generalization. Survival curves were plotted using Kaplan-Meier method and log-rank tests were performed to analyze the association between corticosteroids use and secondary generalization in subgroups defined by anti-AChR antibody status and thymic pathology.
resultsOne hundred and eighty of 572 MG patients who underwent robotic thymectomy were eligible for inclusion, of whom 110 (61.1%) developed a secondary generalized MG over a mean follow-up time of 23.6 months. The presence of a thymoma (HR 1.659, 95% CI (1.52-2.617), P = 0.029) was the only risk factor for secondary generalization in our series. Treating with corticosteroids was associated with a lower conversion rate in ocular myasthenia patients with thymic hyperplasia (n = 55, P = 0.028), but not with other thymic pathologies including thymoma and normal or atrophic thymus.
conclusionsThe conversion rate in ocular myasthenia was high in our series, predicted by the presence of a thymoma. Our findings suggest that corticosteroids can prevent secondary generalization in ocular myasthenia patients with thymic hyperplasia, which requires further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.